Qlucore Receives Approval for 0.5M EUR Installment from the EU
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlucore, a leader in software development for precision cancer diagnostics, received a prestigious grant of 2.5 million Euros during 2024. The grant is divided into four installments. The aim of the project is to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. Within the agreed twelve-month timeframe, Qlucore has passed all the milestones set out for the first part of the project. After passing review, the second payment from the EU of approximately 0.5 million Euros can therefore be processed.
During the project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for AML and bladder cancer. The project spans over three years. The aim is to develop tests for use in clinical laboratories. Another focus is, in collaboration with the pharmaceutical industry, to develop solutions for companion diagnostics.
AML and bladder cancer are of special interest to the project. This is because they harbor multiple RNA modifications. These changes can be utilized to improve diagnosis and treatment. Currently, this information is not fully applied to ensure that the right treatment is used for the right patient. This project aims to change this.
For a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. For this project, Qlucore will build on significant investments in its solutions for acute lymphoblastic leukemia, Qlucore Diagnostics BCP-ALL, both from a software technical point of view and from a quality management system (QMS) point of view. Qlucore Diagnostics BCP-ALL 1.0 was launched in February and has already been sold to the first customer.
“This EU payment will strengthen Qlucore financially. We are at the forefront of RNA-seq-based modern clinical diagnostics and we will continue to work with the milestones set out for this project." says Carl-Johan Ivarsson, CEO of Qlucore.
Intended customers are clinical laboratories across Europe in the first phase, and the US market in the second phase.